## HIV/AIDS Risk Reduction Interventions for African-American Heterosexual Men

0920-09XX

Attachment 8b Local IRB Approval – NYBC

A New York Blood Center

310 E. 67th Street, New York, NY 10065 212/570-3000 Fax 212/570-3195 INSTITUTIONAL REVIEW BOARD (IRB) Phone: 212-570-3038; Fax: 212-570-3343 E-Mail: nmoynihan@nybloodcenter.org

## **MEMORANDUM**

TO: Beryl Koblin, Ph.D.

FROM: Beau Mitchell, M.D. IRB Co-Chair

DATE: March 16, 2010

RE: IRB# 614-10

New Study Final Approval

## **VOTING DEFERRED FROM PREVIOUS MEETING: 2/16/10**

**IRB# 614-10**: Review of Dr. Koblin's responses to Board issues and questions from the February 16, 2010 meeting. The Board had voted to defer final review to March 16, 2010 if responses were received prior to this meeting. PI's responses received on March 12, 2010 and were sent electronically to the Board the same day. Modified March Agenda resent to Board members electronically to reflect this additional Agenda item.

The Board voted unanimously to accept the responses. Fifteen votes for, no abstentions.

IRB approval for this protocol expires on 3/15/11. It is your responsibility to ensure that a complete application for continuing review and approval (renewal) is submitted by the required time: 15 days before the IRB monthly meeting prior to your expiration date.

## \*\*\*\*\*

<u>PLEASE NOTE</u>: Federal regulations require that any serious untoward reactions must be reported to the Board immediately. These regulations also require that any changes in the protocol and/or the consent form must be approved by the Institutional Review Board before use. The termination of a protocol is also considered a change which must be reported to the IRB.